SF
INO icon

Synovus Financial’s Inovio Pharmaceuticals INO Stock Holding History

Synovus Financial’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-79
Closed -$6K – 948
2017
Q1 		$6K Hold
79
– – ﹤0.01% 1003
2016
Q4 		$7K Hold
79
– – ﹤0.01% 953
2016
Q3 		$9K Hold
79
– – ﹤0.01% 904
2016
Q2 		$9K Hold
79
– – ﹤0.01% 856
2016
Q1 		$8K Hold
79
– – ﹤0.01% 869
2015
Q4 		$6K Hold
79
– – ﹤0.01% 899
2015
Q3 		$5K Hold
79
– – ﹤0.01% 878
2015
Q2 		$8K Buy
+79
New +$8.44K ﹤0.01% 868

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Synovus Financial's INO Position: Q2 2017 in Review

Synovus Financial sold out of Inovio Pharmaceuticals (INO) in Q2 2017, closing a stake of 79 shares — an estimated $6K sold.

Synovus Financial first reported a position in INO in Q2 2015 and held it in 8 quarters. The position peaked at $9K in Q3 2016. 118 funds tracked by Wall St. Rank hold INO as of Q2 2017.

  • Synovus Financial reported no remaining Inovio Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Synovus Financial sold 79 Inovio Pharmaceuticals shares in Q2 2017, an estimated $6K.
  • Synovus Financial first reported a position in Inovio Pharmaceuticals in Q2 2015 and held it in 8 quarters.
  • Synovus Financial's Inovio Pharmaceuticals position peaked at $9K in Q3 2016.
  • 118 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2017.

Based on Synovus Financial's 13F filing for Q2 2017, filed 9 Aug 2017.